KEGG   PATHWAY: hsa05200Help
Entry
hsa05200                    Pathway                                

Name
Pathways in cancer - Homo sapiens (human)
Class
Human Diseases; Cancers
BRITE hierarchy
Pathway map
Pathways in cancer
hsa05200

All organismsOrtholog table
Disease
H00559  
von Hippel-Lindau syndrome
H00646  
Odontoonychodermal dysplasia
H00857  
Oligodontia-colorectal cancer syndrome
H00881  
Li-Fraumeni syndrome
H00895  
Basal cell nevus syndrome
H00947  
Pilomatricoma
H01007  
Choroid plexus papilloma
H01023  
Juvenile polyposis syndrome
H01025  
Familial adenomatous polyposis
Drug
D00075  
Testosterone (JAN/USP)
D00289  
Danazol (JP17/USP/INN)
D00586  
Flutamide (JP17/USP/INN)
D00753  
Sirolimus (JAN/USAN/INN)
D00961  
Bicalutamide (JAN/USP/INN)
D00965  
Nilutamide (USAN/INN)
D01301  
Metenolone enanthate (JP17)
D01441  
Imatinib mesilate (JAN)
D01977  
Gefitinib (JAN/USAN/INN)
D02714  
Everolimus (JAN/USAN/INN)
D02815  
Alitretinoin (USAN)
D03106  
Bexarotene (JAN/USAN/INN)
D03218  
Axitinib (JAN/USAN)
D03252  
Bosutinib (USAN)
D03257  
Trastuzumab (genetical recombination) (JAN)
D03455  
Cetuximab (genetical recombination) (JAN)
D03658  
Dasatinib (INN)
D04014  
Enzastaurin hydrochloride (JAN/USAN)
D04023  
Erlotinib hydrochloride (JAN/USAN)
D04024  
Lapatinib tosilate hydrate (JAN)
D04162  
Fenretinide (USAN/INN)
D04696  
Lestaurtinib (USAN/INN)
D05029  
Midostaurin (USAN/INN)
D05350  
Panitumumab (genetical recombination) (JAN)
D05380  
Pazopanib hydrochloride (JAN/USAN)
D05386  
Pegaptanib sodium (JAN/USAN)
D05819  
Semaxanib (USAN/INN)
D06005  
Tandutinib (USAN/INN)
D06068  
Temsirolimus (JAN/USAN/INN)
D06272  
Sorafenib tosilate (JAN)
D06285  
Vatalanib (USAN/INN)
D06320  
Vorinostat (JAN/USAN)
D06402  
Sunitinib malate (JAN/USAN)
D06407  
Vandetanib (JAN/USAN/INN)
D06409  
Bevacizumab (genetical recombination) (JAN)
D06413  
Nilotinib hydrochloride hydrate (JAN)
D06414  
Dasatinib hydrate (JAN)
D06637  
Romidepsin (JAN/USAN/INN)
D07907  
Erlotinib (INN)
D08066  
Imatinib (INN)
D08108  
Lapatinib (INN)
D08279  
Tozasertib (USAN)
D08344  
Tozasertib lactate (USAN)
D08524  
Sorafenib (USAN/INN)
D08552  
Sunitinib (INN)
D08870  
Belinostat (USAN/INN)
D08881  
Cediranib (USAN/INN)
D08883  
Cediranib maleate (JAN/USAN)
D08900  
Ridaforolimus (JAN/USAN)
D08950  
Neratinib (INN/USAN)
D08953  
Nilotinib (USAN/INN)
D09328  
Cixutumumab (USAN)
D09338  
Entinostat (USAN/INN)
D09345  
Figitumumab (USAN)
D09357  
Mocetinostat dihydrobromide (USAN)
D09574  
Aflibercept (genetical recombination) (JAN)
D09641  
Mocetinostat (USAN/INN)
D09659  
Rilotumumab (USAN/INN)
D09724  
Afatinib (USAN/INN)
D09733  
Afatinib maleate (JAN)
D09746  
Dalotuzumab (USAN)
D09864  
Amuvatinib (USAN/INN)
D09865  
Amuvatinib hydrochloride (USAN)
D09908  
Ganitumab (USAN/INN)
D09909  
Gataparsen (USAN/INN)
D09910  
Gataparsen sodium (USAN)
D09919  
Lenvatinib (USAN/INN)
D09920  
Lenvatinib mesilate (JAN)
D09950  
Ponatinib (USAN/INN)
D09951  
Ponatinib hydrochloride (JAN/USAN)
D09955  
Quizartinib (USAN/INN)
D09956  
Quizartinib dihydrochloride (USAN)
D09980  
Trastuzumab emtansine (genetical recombination) (JAN)
D09992  
Vismodegib (USAN/INN)
D09996  
Vemurafenib (JAN/USAN/INN)
D10019  
Panobinostat lactate (JAN)
D10031  
Zalutumumab (USAN/INN)
D10060  
Abexinostat (USAN)
D10062  
Cabozantinib (USAN)
D10076  
Olcorolimus (USAN)
D10084  
Abexinostat hydrochloride (USAN)
D10102  
Crenolanib (USAN)
D10103  
Crenolanib besylate (USAN)
D10123  
Ficlatuzumab (USAN)
D10126  
Ganetespib (USAN)
D10137  
Regorafenib hydrate (JAN)
D10138  
Regorafenib (USAN/INN)
D10164  
Sepantronium bromide (JAN/USAN)
D10173  
Tivantinib (JAN/USAN/INN)
D10189  
Pictilisib (USAN)
D10218  
Enzalutamide (JAN/USAN)
D10319  
Panobinostat (USAN/INN)
D10334  
Rebastinib (USAN)
D10372  
Palbociclib (JAN/USAN)
D10381  
Afuresertib (USAN)
D10382  
Afuresertib hydrochloride (USAN)
D10396  
Nintedanib ethanesulfonate (JAN)
D10399  
Rebastinib Tosylate (USAN)
D10410  
Vantictumab (USAN)
D10423  
Ilorasertib (USAN)
D10426  
Pimasertib (USAN/INN)
D10437  
Galunisertib (USAN)
D10481  
Nintedanib (USAN/INN)
D10486  
Pimasertib hydrochloride (USAN)
D10636  
Glasdegib (USAN/INN)
D10688  
Abemaciclib (USAN)
D10709  
Gilteritinib (USAN/INN)
D10717  
Napabucasin (USAN/INN)
D10718  
Omipalisib (USAN/INN)
D10719  
Onalespib (USAN/INN)
Organism
Homo sapiens (human) [GN:hsa]
Gene
1630  
DCC; DCC netrin 1 receptor [KO:K06765]
836  
CASP3; caspase 3 [KO:K02187] [EC:3.4.22.56]
842  
CASP9; caspase 9 [KO:K04399] [EC:3.4.22.62]
26060  
APPL1; adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 [KO:K08733]
999  
CDH1; cadherin 1 [KO:K05689]
1499  
CTNNB1; catenin beta 1 [KO:K02105]
29119  
CTNNA3; catenin alpha 3 [KO:K05691]
1495  
CTNNA1; catenin alpha 1 [KO:K05691]
1496  
CTNNA2; catenin alpha 2 [KO:K05691]
8312  
AXIN1; axin 1 [KO:K02157]
8313  
AXIN2; axin 2 [KO:K04385]
324  
APC; adenomatous polyposis coli [KO:K02085]
10297  
APC2; adenomatosis polyposis coli 2 [KO:K02085]
2932  
GSK3B; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26]
6932  
TCF7; transcription factor 7 (T-cell specific, HMG-box) [KO:K02620]
83439  
TCF7L1; transcription factor 7 like 1 [KO:K04490]
6934  
TCF7L2; transcription factor 7 like 2 [KO:K04491]
51176  
LEF1; lymphoid enhancer binding factor 1 [KO:K04492]
332  
BIRC5; baculoviral IAP repeat containing 5 [KO:K08731]
4609  
MYC; v-myc avian myelocytomatosis viral oncogene homolog [KO:K04377]
595  
CCND1; cyclin D1 [KO:K04503]
7471  
WNT1; Wnt family member 1 [KO:K03209]
7472  
WNT2; Wnt family member 2 [KO:K00182]
7482  
WNT2B; Wnt family member 2B [KO:K00182]
7473  
WNT3; Wnt family member 3 [KO:K00312]
89780  
WNT3A; Wnt family member 3A [KO:K00312]
54361  
WNT4; Wnt family member 4 [KO:K00408]
7474  
WNT5A; Wnt family member 5A [KO:K00444]
81029  
WNT5B; Wnt family member 5B [KO:K00444]
7475  
WNT6; Wnt family member 6 [KO:K00445]
7476  
WNT7A; Wnt family member 7A [KO:K00572]
7477  
WNT7B; Wnt family member 7B [KO:K00572]
7478  
WNT8A; Wnt family member 8A [KO:K00714]
7479  
WNT8B; Wnt family member 8B [KO:K00714]
7483  
WNT9A; Wnt family member 9A [KO:K01064]
7484  
WNT9B; Wnt family member 9B [KO:K01064]
7480  
WNT10B; Wnt family member 10B [KO:K01357]
80326  
WNT10A; Wnt family member 10A [KO:K01357]
7481  
WNT11; Wnt family member 11 [KO:K01384]
51384  
WNT16; Wnt family member 16 [KO:K01558]
8321  
FZD1; frizzled class receptor 1 [KO:K02432]
8324  
FZD7; frizzled class receptor 7 [KO:K02432]
2535  
FZD2; frizzled class receptor 2 [KO:K02235]
7976  
FZD3; frizzled class receptor 3 [KO:K02329]
8322  
FZD4; frizzled class receptor 4 [KO:K02354]
7855  
FZD5; frizzled class receptor 5 [KO:K02375]
8325  
FZD8; frizzled class receptor 8 [KO:K02375]
8323  
FZD6; frizzled class receptor 6 [KO:K02376]
11211  
FZD10; frizzled class receptor 10 [KO:K02842]
8326  
FZD9; frizzled class receptor 9 [KO:K02842]
1857  
DVL3; dishevelled segment polarity protein 3 [KO:K02353]
1856  
DVL2; dishevelled segment polarity protein 2 [KO:K02353]
1855  
DVL1; dishevelled segment polarity protein 1 [KO:K02353]
2149  
F2R; coagulation factor II thrombin receptor [KO:K03914]
9002  
F2RL3; F2R like thrombin/trypsin receptor 3 [KO:K04236]
1902  
LPAR1; lysophosphatidic acid receptor 1 [KO:K04289]
9170  
LPAR2; lysophosphatidic acid receptor 2 [KO:K04291]
23566  
LPAR3; lysophosphatidic acid receptor 3 [KO:K04294]
2846  
LPAR4; lysophosphatidic acid receptor 4 [KO:K04275]
57121  
LPAR5; lysophosphatidic acid receptor 5 [KO:K08390]
10161  
LPAR6; lysophosphatidic acid receptor 6 [KO:K04273]
185  
AGTR1; angiotensin II receptor type 1 [KO:K04166]
2768  
GNA12; G protein subunit alpha 12 [KO:K04346]
10672  
GNA13; G protein subunit alpha 13 [KO:K04639]
23365  
ARHGEF12; Rho guanine nucleotide exchange factor 12 [KO:K07532]
9826  
ARHGEF11; Rho guanine nucleotide exchange factor 11 [KO:K12331]
9138  
ARHGEF1; Rho guanine nucleotide exchange factor 1 [KO:K12330]
57449  
PLEKHG5; pleckstrin homology and RhoGEF domain containing G5 [KO:K19464]
387  
RHOA; ras homolog family member A [KO:K04513]
6093  
ROCK1; Rho associated coiled-coil containing protein kinase 1 [KO:K04514] [EC:2.7.11.1]
9475  
ROCK2; Rho associated coiled-coil containing protein kinase 2 [KO:K17388] [EC:2.7.11.1]
6387  
CXCL12; C-X-C motif chemokine ligand 12 [KO:K10031]
7852  
CXCR4; C-X-C motif chemokine receptor 4 [KO:K04189]
2770  
GNAI1; G protein subunit alpha i1 [KO:K04630]
2773  
GNAI3; G protein subunit alpha i3 [KO:K04630]
2771  
GNAI2; G protein subunit alpha i2 [KO:K04630]
5731  
PTGER1; prostaglandin E receptor 1 [KO:K04258]
5732  
PTGER2; prostaglandin E receptor 2 [KO:K04259]
5733  
PTGER3; prostaglandin E receptor 3 [KO:K04260]
5734  
PTGER4; prostaglandin E receptor 4 [KO:K04261]
2778  
GNAS; GNAS complex locus [KO:K04632]
107  
ADCY1; adenylate cyclase 1 (brain) [KO:K08041] [EC:4.6.1.1]
108  
ADCY2; adenylate cyclase 2 (brain) [KO:K08042] [EC:4.6.1.1]
109  
ADCY3; adenylate cyclase 3 [KO:K08043] [EC:4.6.1.1]
196883  
ADCY4; adenylate cyclase 4 [KO:K08044] [EC:4.6.1.1]
111  
ADCY5; adenylate cyclase 5 [KO:K08045] [EC:4.6.1.1]
112  
ADCY6; adenylate cyclase 6 [KO:K08046] [EC:4.6.1.1]
113  
ADCY7; adenylate cyclase 7 [KO:K08047] [EC:4.6.1.1]
114  
ADCY8; adenylate cyclase 8 (brain) [KO:K08048] [EC:4.6.1.1]
115  
ADCY9; adenylate cyclase 9 [KO:K08049] [EC:4.6.1.1]
5566  
PRKACA; protein kinase cAMP-activated catalytic subunit alpha [KO:K04345] [EC:2.7.11.11]
5567  
PRKACB; protein kinase cAMP-activated catalytic subunit beta [KO:K04345] [EC:2.7.11.11]
5568  
PRKACG; protein kinase cAMP-activated catalytic subunit gamma [KO:K04345] [EC:2.7.11.11]
2782  
GNB1; G protein subunit beta 1 [KO:K04536]
2783  
GNB2; G protein subunit beta 2 [KO:K04537]
2784  
GNB3; G protein subunit beta 3 [KO:K07825]
59345  
GNB4; G protein subunit beta 4 [KO:K04538]
10681  
GNB5; G protein subunit beta 5 [KO:K04539]
54331  
GNG2; G protein subunit gamma 2 [KO:K07826]
2785  
GNG3; G protein subunit gamma 3 [KO:K04540]
2786  
GNG4; G protein subunit gamma 4 [KO:K04541]
2787  
GNG5; G protein subunit gamma 5 [KO:K04542]
2788  
GNG7; G protein subunit gamma 7 [KO:K04543]
94235  
GNG8; G protein subunit gamma 8 [KO:K04544]
2790  
GNG10; G protein subunit gamma 10 [KO:K04545]
2791  
GNG11; G protein subunit gamma 11 [KO:K04546]
55970  
GNG12; G protein subunit gamma 12 [KO:K04347]
51764  
GNG13; G protein subunit gamma 13 [KO:K04547]
2792  
GNGT1; G protein subunit gamma transducin 1 [KO:K04548]
2793  
GNGT2; G protein subunit gamma transducin 2 [KO:K04549]
1284  
COL4A2; collagen type IV alpha 2 [KO:K06237]
1286  
COL4A4; collagen type IV alpha 4 [KO:K06237]
1288  
COL4A6; collagen type IV alpha 6 [KO:K06237]
1282  
COL4A1; collagen type IV alpha 1 [KO:K06237]
1287  
COL4A5; collagen type IV alpha 5 [KO:K06237]
1285  
COL4A3; collagen type IV alpha 3 [KO:K06237]
284217  
LAMA1; laminin subunit alpha 1 [KO:K05637]
3908  
LAMA2; laminin subunit alpha 2 [KO:K05637]
3909  
LAMA3; laminin subunit alpha 3 [KO:K06240]
3911  
LAMA5; laminin subunit alpha 5 [KO:K06240]
3910  
LAMA4; laminin subunit alpha 4 [KO:K06241]
3912  
LAMB1; laminin subunit beta 1 [KO:K05636]
3913  
LAMB2; laminin subunit beta 2 [KO:K06243]
3914  
LAMB3; laminin subunit beta 3 [KO:K06244]
22798  
LAMB4; laminin subunit beta 4 [KO:K06245]
3915  
LAMC1; laminin subunit gamma 1 [KO:K05635]
3918  
LAMC2; laminin subunit gamma 2 [KO:K06246]
10319  
LAMC3; laminin subunit gamma 3 [KO:K06247]
2335  
FN1; fibronectin 1 [KO:K05717]
3673  
ITGA2; integrin subunit alpha 2 [KO:K06481]
3674  
ITGA2B; integrin subunit alpha 2b [KO:K06476]
3675  
ITGA3; integrin subunit alpha 3 [KO:K06482]
3655  
ITGA6; integrin subunit alpha 6 [KO:K06485]
3685  
ITGAV; integrin subunit alpha V [KO:K06487]
3688  
ITGB1; integrin subunit beta 1 [KO:K05719]
5747  
PTK2; protein tyrosine kinase 2 [KO:K05725] [EC:2.7.10.2]
5290  
PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
5293  
PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
5291  
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
5294  
PIK3CG; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma [KO:K00922] [EC:2.7.1.153]
5295  
PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
23533  
PIK3R5; phosphoinositide-3-kinase regulatory subunit 5 [KO:K02649]
5296  
PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
8503  
PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
5728  
PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.67 3.1.3.48 3.1.3.16]
4824  
NKX3-1; NK3 homeobox 1 [KO:K09348]
207  
AKT1; v-akt murine thymoma viral oncogene homolog 1 [KO:K04456] [EC:2.7.11.1]
208  
AKT2; v-akt murine thymoma viral oncogene homolog 2 [KO:K04456] [EC:2.7.11.1]
10000  
AKT3; v-akt murine thymoma viral oncogene homolog 3 [KO:K04456] [EC:2.7.11.1]
1147  
CHUK; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
3551  
IKBKB; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta [KO:K07209] [EC:2.7.11.10]
8517  
IKBKG; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma [KO:K07210]
4792  
NFKBIA; NFKB inhibitor alpha [KO:K04734]
4790  
NFKB1; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [KO:K02580]
4791  
NFKB2; nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 [KO:K04469]
5970  
RELA; v-rel avian reticuloendotheliosis viral oncogene homolog A [KO:K04735]
5743  
PTGS2; prostaglandin-endoperoxide synthase 2 [KO:K11987] [EC:1.14.99.1]
4843  
NOS2; nitric oxide synthase 2 [KO:K13241] [EC:1.14.13.39]
596  
BCL2; B-cell CLL/lymphoma 2 [KO:K02161]
329  
BIRC2; baculoviral IAP repeat containing 2 [KO:K16060]
330  
BIRC3; baculoviral IAP repeat containing 3 [KO:K16060]
331  
XIAP; X-linked inhibitor of apoptosis [KO:K04725] [EC:2.3.2.27]
79444  
BIRC7; baculoviral IAP repeat containing 7 [KO:K16061]
112401  
BIRC8; baculoviral IAP repeat containing 8 [KO:K16061]
598  
BCL2L1; BCL2 like 1 [KO:K04570]
7185  
TRAF1; TNF receptor associated factor 1 [KO:K03172]
7186  
TRAF2; TNF receptor associated factor 2 [KO:K03173] [EC:2.3.2.27]
7187  
TRAF3; TNF receptor associated factor 3 [KO:K03174]
9618  
TRAF4; TNF receptor associated factor 4 [KO:K09848]
7188  
TRAF5; TNF receptor associated factor 5 [KO:K09849]
7189  
TRAF6; TNF receptor associated factor 6 [KO:K03175] [EC:2.3.2.27]
2475  
MTOR; mechanistic target of rapamycin [KO:K07203] [EC:2.7.11.1]
572  
BAD; BCL2 associated agonist of cell death [KO:K02158]
2308  
FOXO1; forkhead box O1 [KO:K07201]
4193  
MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27]
7157  
TP53; tumor protein p53 [KO:K04451]
1027  
CDKN1B; cyclin-dependent kinase inhibitor 1B [KO:K06624]
1026  
CDKN1A; cyclin-dependent kinase inhibitor 1A [KO:K06625]
613  
BCR; breakpoint cluster region [KO:K08878] [EC:2.7.11.1]
25  
ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase [KO:K06619] [EC:2.7.10.2]
1398  
CRK; v-crk avian sarcoma virus CT10 oncogene homolog [KO:K04438]
1399  
CRKL; v-crk avian sarcoma virus CT10 oncogene homolog-like [KO:K04438]
23624  
CBLC; Cbl proto-oncogene C, E3 ubiquitin protein ligase [KO:K04707] [EC:2.3.2.27]
867  
CBL; Cbl proto-oncogene, E3 ubiquitin protein ligase [KO:K04707] [EC:2.3.2.27]
868  
CBLB; Cbl proto-oncogene B, E3 ubiquitin protein ligase [KO:K04707] [EC:2.3.2.27]
6776  
STAT5A; signal transducer and activator of transcription 5A [KO:K11223]
6777  
STAT5B; signal transducer and activator of transcription 5B [KO:K11224]
623  
BDKRB1; bradykinin receptor B1 [KO:K03915]
624  
BDKRB2; bradykinin receptor B2 [KO:K03916]
1909  
EDNRA; endothelin receptor type A [KO:K04197]
1910  
EDNRB; endothelin receptor type B [KO:K04198]
2776  
GNAQ; G protein subunit alpha q [KO:K04634]
2767  
GNA11; G protein subunit alpha 11 [KO:K04635]
23236  
PLCB1; phospholipase C beta 1 [KO:K05858] [EC:3.1.4.11]
5330  
PLCB2; phospholipase C beta 2 [KO:K05858] [EC:3.1.4.11]
5331  
PLCB3; phospholipase C beta 3 [KO:K05858] [EC:3.1.4.11]
5332  
PLCB4; phospholipase C beta 4 [KO:K05858] [EC:3.1.4.11]
5578  
PRKCA; protein kinase C alpha [KO:K02677] [EC:2.7.11.13]
5579  
PRKCB; protein kinase C beta [KO:K19662] [EC:2.7.11.13]
5582  
PRKCG; protein kinase C gamma [KO:K19663] [EC:2.7.11.13]
10125  
RASGRP1; RAS guanyl releasing protein 1 [KO:K04350]
10235  
RASGRP2; RAS guanyl releasing protein 2 [KO:K12361]
25780  
RASGRP3; RAS guanyl releasing protein 3 [KO:K12362]
115727  
RASGRP4; RAS guanyl releasing protein 4 [KO:K12363]
3716  
JAK1; Janus kinase 1 [KO:K11217] [EC:2.7.10.2]
6774  
STAT3; signal transducer and activator of transcription 3 (acute-phase response factor) [KO:K04692]
6772  
STAT1; signal transducer and activator of transcription 1 [KO:K11220]
7422  
VEGFA; vascular endothelial growth factor A [KO:K05448]
7423  
VEGFB; vascular endothelial growth factor B [KO:K16858]
5228  
PGF; placental growth factor [KO:K16859]
7424  
VEGFC; vascular endothelial growth factor C [KO:K05449]
2277  
FIGF; c-fos induced growth factor (vascular endothelial growth factor D) [KO:K05449]
7039  
TGFA; transforming growth factor alpha [KO:K08774]
1950  
EGF; epidermal growth factor [KO:K04357]
1956  
EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
2064  
ERBB2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1]
5154  
PDGFA; platelet derived growth factor subunit A [KO:K04359]
5155  
PDGFB; platelet derived growth factor subunit B [KO:K17386]
5156  
PDGFRA; platelet derived growth factor receptor alpha [KO:K04363] [EC:2.7.10.1]
5159  
PDGFRB; platelet derived growth factor receptor beta [KO:K05089] [EC:2.7.10.1]
3479  
IGF1; insulin like growth factor 1 [KO:K05459]
3480  
IGF1R; insulin like growth factor 1 receptor [KO:K05087] [EC:2.7.10.1]
4254  
KITLG; KIT ligand [KO:K05461]
3815  
KIT; KIT proto-oncogene receptor tyrosine kinase [KO:K05091] [EC:2.7.10.1]
2323  
FLT3LG; fms related tyrosine kinase 3 ligand [KO:K05454]
2322  
FLT3; fms related tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
3082  
HGF; hepatocyte growth factor [KO:K05460]
4233  
MET; MET proto-oncogene, receptor tyrosine kinase [KO:K05099] [EC:2.7.10.1]
2246  
FGF1; fibroblast growth factor 1 [KO:K18496]
2247  
FGF2; fibroblast growth factor 2 [KO:K18497]
2248  
FGF3; fibroblast growth factor 3 [KO:K04358]
2249  
FGF4; fibroblast growth factor 4 [KO:K04358]
8822  
FGF17; fibroblast growth factor 17 [KO:K04358]
2251  
FGF6; fibroblast growth factor 6 [KO:K04358]
2252  
FGF7; fibroblast growth factor 7 [KO:K04358]
2253  
FGF8; fibroblast growth factor 8 [KO:K04358]
2254  
FGF9; fibroblast growth factor 9 [KO:K04358]
2255  
FGF10; fibroblast growth factor 10 [KO:K04358]
2256  
FGF11; fibroblast growth factor 11 [KO:K04358]
2257  
FGF12; fibroblast growth factor 12 [KO:K04358]
2258  
FGF13; fibroblast growth factor 13 [KO:K04358]
2259  
FGF14; fibroblast growth factor 14 [KO:K04358]
8823  
FGF16; fibroblast growth factor 16 [KO:K04358]
2250  
FGF5; fibroblast growth factor 5 [KO:K04358]
8817  
FGF18; fibroblast growth factor 18 [KO:K04358]
9965  
FGF19; fibroblast growth factor 19 [KO:K04358]
26281  
FGF20; fibroblast growth factor 20 [KO:K04358]
26291  
FGF21; fibroblast growth factor 21 [KO:K04358]
27006  
FGF22; fibroblast growth factor 22 [KO:K04358]
8074  
FGF23; fibroblast growth factor 23 [KO:K04358]
2260  
FGFR1; fibroblast growth factor receptor 1 [KO:K04362] [EC:2.7.10.1]
2263  
FGFR2; fibroblast growth factor receptor 2 [KO:K05093] [EC:2.7.10.1]
2261  
FGFR3; fibroblast growth factor receptor 3 [KO:K05094] [EC:2.7.10.1]
2885  
GRB2; growth factor receptor bound protein 2 [KO:K04364]
6654  
SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
6655  
SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
3265  
HRAS; Harvey rat sarcoma viral oncogene homolog [KO:K02833]
3845  
KRAS; Kirsten rat sarcoma viral oncogene homolog [KO:K07827]
4893  
NRAS; neuroblastoma RAS viral (v-ras) oncogene homolog [KO:K07828]
369  
ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
673  
BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
5894  
RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
5604  
MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
5605  
MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
5594  
MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
5595  
MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
3725  
JUN; jun proto-oncogene [KO:K04448]
2353  
FOS; FBJ murine osteosarcoma viral oncogene homolog [KO:K04379]
4312  
MMP1; matrix metallopeptidase 1 [KO:K01388] [EC:3.4.24.7]
4313  
MMP2; matrix metallopeptidase 2 [KO:K01398] [EC:3.4.24.24]
4318  
MMP9; matrix metallopeptidase 9 [KO:K01403] [EC:3.4.24.35]
3576  
CXCL8; C-X-C motif chemokine ligand 8 [KO:K10030]
1019  
CDK4; cyclin-dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
5979  
RET; ret proto-oncogene [KO:K05126] [EC:2.7.10.1]
8030  
CCDC6; coiled-coil domain containing 6 [KO:K09288]
8031  
NCOA4; nuclear receptor coactivator 4 [KO:K09289]
4914  
NTRK1; neurotrophic tyrosine kinase, receptor, type 1 [KO:K03176] [EC:2.7.10.1]
7170  
TPM3; tropomyosin 3 [KO:K09290]
7175  
TPR; translocated promoter region, nuclear basket protein [KO:K09291]
10342  
TFG; TRK-fused gene [KO:K09292]
11186  
RASSF1; Ras association domain family member 1 [KO:K09850]
83593  
RASSF5; Ras association domain family member 5 [KO:K08015]
6789  
STK4; serine/threonine kinase 4 [KO:K04411]
1612  
DAPK1; death associated protein kinase 1 [KO:K08803] [EC:2.7.11.1]
1613  
DAPK3; death-associated protein kinase 3 [KO:K08803] [EC:2.7.11.1]
23604  
DAPK2; death-associated protein kinase 2 [KO:K08803] [EC:2.7.11.1]
5335  
PLCG1; phospholipase C gamma 1 [KO:K01116] [EC:3.1.4.11]
5336  
PLCG2; phospholipase C gamma 2 [KO:K05859] [EC:3.1.4.11]
5900  
RALGDS; ral guanine nucleotide dissociation stimulator [KO:K08732]
5898  
RALA; v-ral simian leukemia viral oncogene homolog A (ras related) [KO:K07834]
5899  
RALB; v-ral simian leukemia viral oncogene homolog B [KO:K07835]
10928  
RALBP1; ralA binding protein 1 [KO:K08773]
998  
CDC42; cell division cycle 42 [KO:K04393]
5879  
RAC1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) [KO:K04392]
5880  
RAC2; ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) [KO:K07860]
5881  
RAC3; ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) [KO:K07861]
5599  
MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
5602  
MAPK10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24]
5601  
MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
7849  
PAX8; paired box 8 [KO:K09293]
5468  
PPARG; peroxisome proliferator activated receptor gamma [KO:K08530]
6256  
RXRA; retinoid X receptor alpha [KO:K08524]
6257  
RXRB; retinoid X receptor beta [KO:K08525]
6258  
RXRG; retinoid X receptor gamma [KO:K08526]
5915  
RARB; retinoic acid receptor beta [KO:K08528]
5467  
PPARD; peroxisome proliferator activated receptor delta [KO:K04504]
3728  
JUP; junction plakoglobin [KO:K10056]
7704  
ZBTB16; zinc finger and BTB domain containing 16 [KO:K10055]
5371  
PML; promyelocytic leukemia [KO:K10054]
5914  
RARA; retinoic acid receptor alpha [KO:K08527]
861  
RUNX1; runt related transcription factor 1 [KO:K08367]
862  
RUNX1T1; RUNX1 translocation partner 1 [KO:K10053]
6688  
SPI1; Spi-1 proto-oncogene [KO:K09438]
1050  
CEBPA; CCAAT/enhancer binding protein alpha [KO:K09055]
1438  
CSF2RA; colony stimulating factor 2 receptor alpha subunit [KO:K05066]
1441  
CSF3R; colony stimulating factor 3 receptor [KO:K05061]
1436  
CSF1R; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1]
3569  
IL6; interleukin 6 [KO:K05405]
1029  
CDKN2A; cyclin-dependent kinase inhibitor 2A [KO:K06621]
1869  
E2F1; E2F transcription factor 1 [KO:K17454]
1870  
E2F2; E2F transcription factor 2 [KO:K09389]
1871  
E2F3; E2F transcription factor 3 [KO:K06620]
4149  
MAX; MYC associated factor X [KO:K04453]
9063  
PIAS2; protein inhibitor of activated STAT 2 [KO:K16063]
1030  
CDKN2B; cyclin-dependent kinase inhibitor 2B [KO:K04685]
1021  
CDK6; cyclin-dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
1163  
CKS1B; CDC28 protein kinase regulatory subunit 1B [KO:K02219]
1164  
CKS2; CDC28 protein kinase regulatory subunit 2 [KO:K02219]
6502  
SKP2; S-phase kinase-associated protein 2, E3 ubiquitin protein ligase [KO:K03875]
1017  
CDK2; cyclin-dependent kinase 2 [KO:K02206] [EC:2.7.11.22]
898  
CCNE1; cyclin E1 [KO:K06626]
9134  
CCNE2; cyclin E2 [KO:K06626]
5925  
RB1; retinoblastoma 1 [KO:K06618]
4286  
MITF; microphthalmia-associated transcription factor [KO:K09455]
7040  
TGFB1; transforming growth factor beta 1 [KO:K13375]
7042  
TGFB2; transforming growth factor beta 2 [KO:K13376]
7043  
TGFB3; transforming growth factor beta 3 [KO:K13377]
7046  
TGFBR1; transforming growth factor beta receptor I [KO:K04674] [EC:2.7.11.30]
7048  
TGFBR2; transforming growth factor beta receptor II [KO:K04388] [EC:2.7.11.30]
4087  
SMAD2; SMAD family member 2 [KO:K04500]
4088  
SMAD3; SMAD family member 3 [KO:K04500]
4089  
SMAD4; SMAD family member 4 [KO:K04501]
2122  
MECOM; MDS1 and EVI1 complex locus [KO:K04462]
1487  
CTBP1; C-terminal binding protein 1 [KO:K04496]
1488  
CTBP2; C-terminal binding protein 2 [KO:K04496]
3065  
HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
3066  
HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
4292  
MLH1; mutL homolog 1 [KO:K08734]
4436  
MSH2; mutS homolog 2 [KO:K08735]
4437  
MSH3; mutS homolog 3 [KO:K08736]
2956  
MSH6; mutS homolog 6 [KO:K08737]
581  
BAX; BCL2-associated X protein [KO:K02159]
675  
BRCA2; breast cancer 2 [KO:K08775]
5888  
RAD51; RAD51 recombinase [KO:K04482]
356  
FASLG; Fas ligand [KO:K04389]
355  
FAS; Fas cell surface death receptor [KO:K04390]
8772  
FADD; Fas associated via death domain [KO:K02373]
841  
CASP8; caspase 8 [KO:K04398] [EC:3.4.22.61]
637  
BID; BH3 interacting domain death agonist [KO:K04726]
54205  
CYCS; cytochrome c, somatic [KO:K08738]
7428  
VHL; von Hippel-Lindau tumor suppressor [KO:K03871]
6921  
TCEB1; transcription elongation factor B subunit 1 [KO:K03872]
6923  
TCEB2; transcription elongation factor B subunit 2 [KO:K03873]
9978  
RBX1; ring-box 1, E3 ubiquitin protein ligase [KO:K03868]
8453  
CUL2; cullin 2 [KO:K03870]
54583  
EGLN1; egl-9 family hypoxia-inducible factor 1 [KO:K09592] [EC:1.14.11.29]
112399  
EGLN3; egl-9 family hypoxia-inducible factor 3 [KO:K09592] [EC:1.14.11.29]
112398  
EGLN2; egl-9 family hypoxia-inducible factor 2 [KO:K09592] [EC:1.14.11.29]
2271  
FH; fumarate hydratase [KO:K01679] [EC:4.2.1.2]
3091  
HIF1A; hypoxia inducible factor 1 alpha subunit [KO:K08268]
2034  
EPAS1; endothelial PAS domain protein 1 [KO:K09095]
405  
ARNT; aryl hydrocarbon receptor nuclear translocator [KO:K09097]
9915  
ARNT2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589]
1387  
CREBBP; CREB binding protein [KO:K04498] [EC:2.3.1.48]
2033  
EP300; E1A binding protein p300 [KO:K04498] [EC:2.3.1.48]
6513  
SLC2A1; solute carrier family 2 member 1 [KO:K07299]
6469  
SHH; sonic hedgehog [KO:K11988]
5727  
PTCH1; patched 1 [KO:K06225]
6608  
SMO; smoothened, frizzled class receptor [KO:K06226]
27148  
STK36; serine/threonine kinase 36 [KO:K06228] [EC:2.7.11.1]
51684  
SUFU; SUFU negative regulator of hedgehog signaling [KO:K06229]
2735  
GLI1; GLI family zinc finger 1 [KO:K16797]
2736  
GLI2; GLI family zinc finger 2 [KO:K16798]
2737  
GLI3; GLI family zinc finger 3 [KO:K06230]
650  
BMP2; bone morphogenetic protein 2 [KO:K04662]
652  
BMP4; bone morphogenetic protein 4 [KO:K04662]
64399  
HHIP; hedgehog interacting protein [KO:K06231]
8643  
PTCH2; patched 2 [KO:K11101]
367  
AR; androgen receptor [KO:K08557]
3320  
HSP90AA1; heat shock protein 90kDa alpha family class A member 1 [KO:K04079]
3326  
HSP90AB1; heat shock protein 90kDa alpha family class B member 1 [KO:K04079]
7184  
HSP90B1; heat shock protein 90kDa beta family member 1 [KO:K09487]
354  
KLK3; kallikrein related peptidase 3 [KO:K01351] [EC:3.4.21.77]
2113  
ETS1; ETS proto-oncogene 1, transcription factor [KO:K02678]
2950  
GSTP1; glutathione S-transferase pi 1 [KO:K00799] [EC:2.5.1.18]
5337  
PLD1; phospholipase D1 [KO:K01115] [EC:3.1.4.4]
8900  
CCNA1; cyclin A1 [KO:K06627]
Compound
C00076  
Calcium cation
C00122  
Fumarate
C00149  
(S)-Malate
C00165  
Diacylglycerol
C00187  
Cholesterol
C00280  
Androstenedione
C00306  
Bradykinin
C00410  
Progesterone
C00416  
Phosphatidate
C00535  
Testosterone
C00575  
3',5'-Cyclic AMP
C00584  
Prostaglandin E2
C00681  
1-Acyl-sn-glycerol 3-phosphate
C00735  
Cortisol
C00752  
Thrombin
C00762  
Cortisone
C00777  
Retinoate
C00951  
Estradiol-17beta
C01227  
Dehydroepiandrosterone
C01245  
D-myo-Inositol 1,4,5-trisphosphate
C02135  
Angiotensin II
C03917  
Dihydrotestosterone
C05981  
Phosphatidylinositol-3,4,5-trisphosphate
C07653  
Flutamide
C15493  
9-cis-Retinoic acid
C16010  
Endothelin-1
C16038  
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Reference
  Authors
Weinberg RA.
  Title
The biology of cancer
  Journal
Garland Science, Taylor & Francis Group, LLC (2007)
Reference
  Authors
Hanahan D, Weinberg RA
  Title
The hallmarks of cancer.
  Journal
Cell 100:57-70 (2000)
Reference
  Authors
Grady WM.
  Title
Genomic instability and colon cancer.
  Journal
Cancer Metastasis Rev 23:11-27 (2004)
Reference
  Authors
Soreide K, Janssen EA, Soiland H, Korner H, Baak JP.
  Title
Microsatellite instability in colorectal cancer.
  Journal
Br J Surg 93:395-406 (2006)
Reference
  Authors
Anwar S, Hall C, White J, Deakin M, Farrell W, Elder JB.
  Title
Hereditary non-polyposis colorectal cancer: an updated review.
  Journal
Eur J Surg Oncol 26:635-45 (2000)
Reference
  Authors
Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y.
  Title
Colorectal cancer: genetics of development and metastasis.
  Journal
J Gastroenterol 41:185-92 (2006)
Reference
  Authors
Lynch HT, de la Chapelle A.
  Title
Hereditary colorectal cancer.
  Journal
N Engl J Med 348:919-32 (2003)
Reference
  Authors
Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C.
  Title
The significance of unstable chromosomes in colorectal cancer.
  Journal
Nat Rev Cancer 3:695-701 (2003)
Reference
  Authors
Behrens J.
  Title
Cadherins and catenins: role in signal transduction and tumor progression.
  Journal
Cancer Metastasis Rev 18:15-30 (1999)
Reference
  Authors
Behrens J.
  Title
The role of the Wnt signalling pathway in colorectal tumorigenesis.
  Journal
Biochem Soc Trans 33:672-5 (2005)
Reference
  Authors
Behrens J, Lustig B.
  Title
The Wnt connection to tumorigenesis.
  Journal
Int J Dev Biol 48:477-87 (2004)
Reference
PMID:9196022
  Authors
Polakis P.
  Title
The adenomatous polyposis coli (APC) tumor suppressor.
  Journal
Biochim Biophys Acta 1332:F127-47 (1997)
Reference
  Authors
Janssen KP.
  Title
Murine models of colorectal cancer: studying the role of oncogenic K-ras.
  Journal
Cell Mol Life Sci 60:495-506 (2003)
Reference
  Authors
Adjei AA.
  Title
Blocking oncogenic Ras signaling for cancer therapy.
  Journal
J Natl Cancer Inst 93:1062-74 (2001)
Reference
  Authors
Arakawa H.
  Title
Netrin-1 and its receptors in tumorigenesis.
  Journal
Nat Rev Cancer 4:978-87 (2004)
Reference
  Authors
Mehlen P, Fearon ER.
  Title
Role of the dependence receptor DCC in colorectal cancer pathogenesis.
  Journal
J Clin Oncol 22:3420-8 (2004)
Reference
  Authors
Peltomaki P.
  Title
DNA mismatch repair and cancer.
  Journal
Mutat Res 488:77-85 (2001)
Reference
  Authors
Li F, Cao Y, Townsend CM Jr, Ko TC.
  Title
TGF-beta signaling in colon cancer cells.
  Journal
World J Surg 29:306-11 (2005)
Reference
  Authors
Roman C, Saha D, Beauchamp R.
  Title
TGF-beta and colorectal carcinogenesis.
  Journal
Microsc Res Tech 52:450-7 (2001)
Reference
  Authors
Watson AJ.
  Title
An overview of apoptosis and the prevention of colorectal cancer.
  Journal
Crit Rev Oncol Hematol 57:107-21 (2006)
Reference
  Authors
Watson AJ.
  Title
Apoptosis and colorectal cancer.
  Journal
Gut 53:1701-9 (2004)
Reference
  Authors
Houlston RS.
  Title
What we could do now: molecular pathology of colorectal cancer.
  Journal
Mol Pathol 54:206-14 (2001)
Reference
  Authors
Von Hoff D, Evans D, Hruban R (ed).
  Title
Pancreatic cancer
  Journal
Jones and Bartlett publishers (2005)
Reference
  Authors
Niitsu Y, Yokota J (ed).
  Title
[Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese)
  Journal
Nankodo (1999)
Reference
  Authors
Bardeesy N, DePinho RA.
  Title
Pancreatic cancer biology and genetics.
  Journal
Nat Rev Cancer 2:897-909 (2002)
Reference
  Authors
Bardeesy N, Sharpless NE, DePinho RA, Merlino G.
  Title
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.
  Journal
Semin Cancer Biol 11:201-18 (2001)
Reference
  Authors
Cowgill SM, Muscarella P.
  Title
The genetics of pancreatic cancer.
  Journal
Am J Surg 186:279-86 (2003)
Reference
  Authors
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.
  Title
Genetics and biology of pancreatic ductal adenocarcinoma.
  Journal
Genes Dev 20:1218-49 (2006)
Reference
  Authors
Shields JM, Pruitt K, McFall A, Shaub A, Der CJ.
  Title
Understanding Ras: 'it ain't over 'til it's over'.
  Journal
Trends Cell Biol 10:147-54 (2000)
Reference
  Authors
Holbro T, Civenni G, Hynes NE.
  Title
The ErbB receptors and their role in cancer progression.
  Journal
Exp Cell Res 284:99-110 (2003)
Reference
  Authors
Marmor MD, Skaria KB, Yarden Y.
  Title
Signal transduction and oncogenesis by ErbB/HER receptors.
  Journal
Int J Radiat Oncol Biol Phys 58:903-13 (2004)
Reference
  Authors
DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.
  Title
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.
  Journal
Oncogene 22:7781-95 (2003)
Reference
  Authors
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.
  Title
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
  Journal
Oncogene 22:319-29 (2003)
Reference
  Authors
Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M.
  Title
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
  Journal
Cancer Lett 201:107-16 (2003)
Reference
  Authors
Schmid RM.
  Title
Genetic basis of pancreatic cancer.
  Journal
Best Pract Res Clin Gastroenterol 16:421-33 (2002)
Reference
  Authors
Elliott RL, Blobe GC.
  Title
Role of transforming growth factor Beta in human cancer.
  Journal
J Clin Oncol 23:2078-93 (2005)
Reference
  Authors
Rudkin TM, Foulkes WD.
  Title
BRCA2: breaks, mistakes and failed separations.
  Journal
Trends Mol Med 11:145-8 (2005)
Reference
  Authors
Venkitaraman AR.
  Title
Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
  Journal
J Cell Sci 114:3591-8 (2001)
Reference
  Authors
Soni D, King JA, Kaye AH, Hovens CM.
  Title
Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge.
  Journal
J Clin Neurosci 12:1-5 (2005)
Reference
  Authors
Zhu Y, Parada LF.
  Title
The molecular and genetic basis of neurological tumours.
  Journal
Nat Rev Cancer 2:616-26 (2002)
Reference
  Authors
Holland EC.
  Title
Gliomagenesis: genetic alterations and mouse models.
  Journal
Nat Rev Genet 2:120-9 (2001)
Reference
  Authors
Bansal K, Liang ML, Rutka JT.
  Title
Molecular biology of human gliomas.
  Journal
Technol Cancer Res Treat 5:185-94 (2006)
Reference
  Authors
Tabuchi K (ed).
  Title
[Gliomas: Research and therapy] (In Japanese)
  Journal
Springer-Verlag Tokyo (2006)
Reference
  Authors
Kapoor GS, O'Rourke DM.
  Title
Mitogenic signaling cascades in glial tumors.
  Journal
Neurosurgery 52:1425-34; discussion 1434-5 (2003)
Reference
  Authors
Hulleman E, Helin K.
  Title
Molecular mechanisms in gliomagenesis.
  Journal
Adv Cancer Res 94:1-27 (2005)
Reference
  Authors
Schlessinger J.
  Title
Cell signaling by receptor tyrosine kinases.
  Journal
Cell 103:211-25 (2000)
Reference
PMID:9643506
  Authors
Ng HK, Lam PY.
  Title
The molecular genetics of central nervous system tumors.
  Journal
Pathology 30:196-202 (1998)
Reference
  Authors
Knobbe CB, Merlo A, Reifenberger G.
  Title
Pten signaling in gliomas.
  Journal
Neuro-oncol 4:196-211 (2002)
Reference
  Authors
Kondo T, Ezzat S, Asa SL.
  Title
Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
  Journal
Nat Rev Cancer 6:292-306 (2006)
Reference
  Authors
Chiloeches A, Marais R.
  Title
Is BRAF the Achilles' Heel of thyroid cancer?
  Journal
Clin Cancer Res 12:1661-4 (2006)
Reference
  Authors
Reddi HV, McIver B, Grebe SK, Eberhardt NL.
  Title
THE PAX8/PPAR{gamma} ONCOGENE IN THYROID TUMORIGENESIS.
  Journal
Endocrinology : (2006)
Reference
  Authors
Santoro M, Melillo RM, Fusco A.
  Title
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
  Journal
Eur J Endocrinol 155:645-653 (2006)
Reference
  Authors
Pierotti MA, Greco A.
  Title
Oncogenic rearrangements of the NTRK1/NGF receptor.
  Journal
Cancer Lett 232:90-8 (2006)
Reference
  Authors
Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.
  Title
Molecular pathology of well-differentiated thyroid carcinomas.
  Journal
Virchows Arch 447:787-93 (2005)
Reference
  Authors
Gimm O.
  Title
Thyroid cancer.
  Journal
Cancer Lett 163:143-56 (2001)
Reference
  Authors
Williams D.
  Title
Cancer after nuclear fallout: lessons from the Chernobyl accident.
  Journal
Nat Rev Cancer 2:543-9 (2002)
Reference
  Authors
Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.
  Title
The molecular pathogenesis of acute myeloid leukemia.
  Journal
Crit Rev Oncol Hematol 56:195-221 (2005)
Reference
  Authors
Tenen DG.
  Title
Disruption of differentiation in human cancer: AML shows the way.
  Journal
Nat Rev Cancer 3:89-101 (2003)
Reference
  Authors
Choudhary C, Muller-Tidow C, Berdel WE, Serve H.
  Title
Signal transduction of oncogenic Flt3.
  Journal
Int J Hematol 82:93-9 (2005)
Reference
  Authors
Stirewalt DL, Radich JP.
  Title
The role of FLT3 in haematopoietic malignancies.
  Journal
Nat Rev Cancer 3:650-65 (2003)
Reference
  Authors
Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.
  Title
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
  Journal
Leukemia 20:911-28 (2006)
Reference
  Authors
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R.
  Title
Normal and oncogenic forms of the receptor tyrosine kinase kit.
  Journal
Stem Cells 23:16-43 (2005)
Reference
  Authors
Lorsbach RB, Downing JR.
  Title
The role of the AML1 transcription factor in leukemogenesis.
  Journal
Int J Hematol 74:258-65 (2001)
Reference
  Authors
Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H.
  Title
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
  Journal
Blood 101:3164-73 (2003)
Reference
  Authors
Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C.
  Title
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
  Journal
Leukemia : (2007)
Reference
  Authors
Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG.
  Title
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
  Journal
Blood 107:3330-8 (2006)
Reference
  Authors
Ren R.
  Title
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
  Journal
Nat Rev Cancer 5:172-83 (2005)
Reference
  Authors
Deininger MW, Goldman JM, Melo JV.
  Title
The molecular biology of chronic myeloid leukemia.
  Journal
Blood 96:3343-56 (2000)
Reference
  Authors
Calabretta B, Perrotti D.
  Title
The biology of CML blast crisis.
  Journal
Blood 103:4010-22 (2004)
Reference
  Authors
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
  Title
The biology of chronic myeloid leukemia.
  Journal
N Engl J Med 341:164-72 (1999)
Reference
  Authors
Mitani K.
  Title
Molecular mechanisms of leukemogenesis by AML1/EVI-1.
  Journal
Oncogene 23:4263-9 (2004)
Reference
  Authors
Dong M, Blobe GC.
  Title
Role of transforming growth factor-beta in hematologic malignancies.
  Journal
Blood 107:4589-96 (2006)
Reference
PMID:9834202
  Authors
Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
  Title
The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
  Journal
Blood 92:4003-12 (1998)
Reference
  Authors
Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
  Title
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
  Journal
Haematologica 88:622-30 (2003)
Reference
  Authors
Baldwin AS.
  Title
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
  Journal
J Clin Invest 107:241-6 (2001)
Reference
  Authors
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.
  Title
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
  Journal
Nat Med 8:1145-52 (2002)
Reference
  Authors
Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC.
  Title
Molecular aetiology and pathogenesis of basal cell carcinoma.
  Journal
Br J Dermatol 152:1108-24 (2005)
Reference
  Authors
Saldanha G, Fletcher A, Slater DN.
  Title
Basal cell carcinoma: a dermatopathological and molecular biological update.
  Journal
Br J Dermatol 148:195-202 (2003)
Reference
  Authors
Daya-Grosjean L, Couve-Privat S.
  Title
Sonic hedgehog signaling in basal cell carcinomas.
  Journal
Cancer Lett 225:181-92 (2005)
Reference
  Authors
Tsai KY, Tsao H.
  Title
The genetics of skin cancer.
  Journal
Am J Med Genet C Semin Med Genet 131C:82-92 (2004)
Reference
  Authors
Athar M, Tang X, Lee JL, Kopelovich L, Kim AL.
  Title
Hedgehog signalling in skin development and cancer.
  Journal
Exp Dermatol 15:667-77 (2006)
Reference
  Authors
Rubin AI, Chen EH, Ratner D.
  Title
Basal-cell carcinoma.
  Journal
N Engl J Med 353:2262-9 (2005)
Reference
  Authors
Saldanha G.
  Title
The Hedgehog signalling pathway and cancer.
  Journal
J Pathol 193:427-32 (2001)
Reference
  Authors
Saldanha G, Ghura V, Potter L, Fletcher A.
  Title
Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.
  Journal
Br J Dermatol 151:157-64 (2004)
Reference
  Authors
Pasca di Magliano M, Hebrok M.
  Title
Hedgehog signalling in cancer formation and maintenance.
  Journal
Nat Rev Cancer 3:903-11 (2003)
Reference
  Authors
Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G.
  Title
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
  Journal
Br J Dermatol 152:43-51 (2005)
Reference
  Authors
Cohen MM Jr.
  Title
The hedgehog signaling network.
  Journal
Am J Med Genet A 123:5-28 (2003)
Reference
  Authors
Yamazaki F, Aragane Y, Kawada A, Tezuka T.
  Title
Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma.
  Journal
Br J Dermatol 145:771-7 (2001)
Reference
  Authors
Erb P, Ji J, Wernli M, Kump E, Glaser A, Buchner SA.
  Title
Role of apoptosis in basal cell and squamous cell carcinoma formation.
  Journal
Immunol Lett 100:68-72 (2005)
Reference
  Authors
Toftgard R.
  Title
Hedgehog signalling in cancer.
  Journal
Cell Mol Life Sci 57:1720-31 (2000)
Reference
  Authors
Miller AJ, Mihm MC Jr.
  Title
Melanoma.
  Journal
N Engl J Med 355:51-65 (2006)
Reference
  Authors
Chin L.
  Title
The genetics of malignant melanoma: lessons from mouse and man.
  Journal
Nat Rev Cancer 3:559-70 (2003)
Reference
  Authors
Takata M, Saida T.
  Title
Genetic alterations in melanocytic tumors.
  Journal
J Dermatol Sci 43:1-10 (2006)
Reference
  Authors
Chudnovsky Y, Khavari PA, Adams AE.
  Title
Melanoma genetics and the development of rational therapeutics.
  Journal
J Clin Invest 115:813-24 (2005)
Reference
  Authors
Merlino G.
  Title
Cancer biology: the weakest link?
  Journal
Nature 436:33-5 (2005)
Reference
  Authors
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.
  Title
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
  Journal
Nature 436:117-22 (2005)
Reference
  Authors
Levy C, Khaled M, Fisher DE.
  Title
MITF: master regulator of melanocyte development and melanoma oncogene.
  Journal
Trends Mol Med 12:406-14 (2006)
Reference
  Authors
Tsao H, Goel V, Wu H, Yang G, Haluska FG.
  Title
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
  Journal
J Invest Dermatol 122:337-41 (2004)
Reference
  Authors
Gruss C, Herlyn M.
  Title
Role of cadherins and matrixins in melanoma.
  Journal
Curr Opin Oncol 13:117-23 (2001)
Reference
  Authors
Thompson JF, Scolyer RA, Kefford RF.
  Title
Cutaneous melanoma.
  Journal
Lancet 365:687-701 (2005)
Reference
  Authors
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.
  Title
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
  Journal
Clin Cancer Res 9:6483-8 (2003)
Reference
  Authors
Hussein MR.
  Title
The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?
  Journal
Tumour Biol 25:200-7 (2004)
Reference
  Authors
Lazar-Molnar E, Hegyesi H, Toth S, Falus A.
  Title
Autocrine and paracrine regulation by cytokines and growth factors in melanoma.
  Journal
Cytokine 12:547-54 (2000)
Reference
  Authors
Cohen HT, McGovern FJ.
  Title
Renal-cell carcinoma.
  Journal
N Engl J Med 353:2477-90 (2005)
Reference
  Authors
Pavlovich CP, Schmidt LS.
  Title
Searching for the hereditary causes of renal-cell carcinoma.
  Journal
Nat Rev Cancer 4:381-93 (2004)
Reference
  Authors
Linehan WM, Walther MM, Zbar B.
  Title
The genetic basis of cancer of the kidney.
  Journal
J Urol 170:2163-72 (2003)
Reference
  Authors
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.
  Title
Met, metastasis, motility and more.
  Journal
Nat Rev Mol Cell Biol 4:915-25 (2003)
Reference
  Authors
Kim WY, Kaelin WG.
  Title
Role of VHL gene mutation in human cancer.
  Journal
J Clin Oncol 22:4991-5004 (2004)
Reference
  Authors
Sudarshan S, Linehan WM, Neckers L.
  Title
HIF and fumarate hydratase in renal cancer.
  Journal
Br J Cancer 96:403-7 (2007)
Reference
  Authors
Sudarshan S, Pinto PA, Neckers L, Linehan WM.
  Title
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
  Journal
Nat Clin Pract Urol 4:104-10 (2007)
Reference
  Authors
Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.
  Title
Understanding familial and non-familial renal cell cancer.
  Journal
Hum Mol Genet 11:2489-98 (2002)
Reference
  Authors
Mitra AP, Datar RH, Cote RJ.
  Title
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
  Journal
J Clin Oncol 24:5552-64 (2006)
Reference
  Authors
Wolff EM, Liang G, Jones PA.
  Title
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
  Journal
Nat Clin Pract Urol 2:502-10 (2005)
Reference
  Authors
Wu XR.
  Title
Urothelial tumorigenesis: a tale of divergent pathways.
  Journal
Nat Rev Cancer 5:713-25 (2005)
Reference
  Authors
Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R.
  Title
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
  Journal
Cancer Res 60:6298-302 (2000)
Reference
  Authors
Bellmunt J, Hussain M, Dinney CP.
  Title
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
  Journal
Crit Rev Oncol Hematol 46 Suppl:S85-104 (2003)
Reference
  Authors
Sugano K, Kakizoe T.
  Title
Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
  Journal
Nat Clin Pract Urol 3:642-52 (2006)
Reference
  Authors
Dunn KL, Espino PS, Drobic B, He S, Davie JR.
  Title
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.
  Journal
Biochem Cell Biol 83:1-14 (2005)
Reference
  Authors
Williams SG, Stein JP.
  Title
Molecular pathways in bladder cancer.
  Journal
Urol Res 32:373-85 (2004)
Reference
  Authors
Nelson WG, De Marzo AM, Isaacs WB.
  Title
Prostate cancer.
  Journal
N Engl J Med 349:366-81 (2003)
Reference
  Authors
Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.
  Title
The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
  Journal
Prostate Cancer Prostatic Dis 8:108-18 (2005)
Reference
  Authors
Pienta KJ, Bradley D.
  Title
Mechanisms underlying the development of androgen-independent prostate cancer.
  Journal
Clin Cancer Res 12:1665-71 (2006)
Reference
  Authors
Feldman BJ, Feldman D.
  Title
The development of androgen-independent prostate cancer.
  Journal
Nat Rev Cancer 1:34-45 (2001)
Reference
  Authors
Heinlein CA, Chang C.
  Title
Androgen receptor in prostate cancer.
  Journal
Endocr Rev 25:276-308 (2004)
Reference
PMID:9422516
  Authors
Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.
  Title
Androgen receptor gene and hormonal therapy failure of prostate cancer.
  Journal
Am J Pathol 152:1-9 (1998)
Reference
  Authors
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.
  Title
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
  Journal
Nat Med 6:703-6 (2000)
Reference
  Authors
Macri E, Loda M.
  Title
Role of p27 in prostate carcinogenesis.
  Journal
Cancer Metastasis Rev 17:337-44 (1998)
Reference
  Authors
Steers WD.
  Title
5alpha-reductase activity in the prostate.
  Journal
Urology 58:17-24; discussion 24 (2001)
Reference
PMID:8069858
  Authors
Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.
  Title
Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.
  Journal
Cancer Res 54:4920-6 (1994)
Reference
  Authors
Grimes CA, Jope RS.
  Title
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.
  Journal
Prog Neurobiol 65:391-426 (2001)
Reference
  Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
  Title
Endometrial cancer.
  Journal
Cell Tissue Res 322:53-61 (2005)
Reference
  Authors
Lax SF.
  Title
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
  Journal
Virchows Arch 444:213-23 (2004)
Reference
  Authors
Shiozawa T, Konishi I.
  Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
  Journal
Int J Clin Oncol 11:13-21 (2006)
Reference
  Authors
Hecht JL, Mutter GL.
  Title
Molecular and pathologic aspects of endometrial carcinogenesis.
  Journal
J Clin Oncol 24:4783-91 (2006)
Reference
  Authors
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.
  Title
Molecular pathology of endometrial hyperplasia and carcinoma.
  Journal
Hum Pathol 32:569-77 (2001)
Reference
  Authors
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.
  Title
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
  Journal
J Clin Oncol 22:3126-32 (2004)
Reference
PMID:7585656
  Authors
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
  Title
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
  Journal
Cancer Res 55:5693-8 (1995)
Reference
  Authors
Kim D, Chung J.
  Title
Akt: versatile mediator of cell survival and beyond.
  Journal
J Biochem Mol Biol 35:106-15 (2002)
Reference
  Authors
Sanchez-Cespedes M.
  Title
Dissecting the genetic alterations involved in lung carcinogenesis.
  Journal
Lung Cancer 40:111-21 (2003)
Reference
  Authors
Kaye FJ.
  Title
Molecular biology of lung cancer.
  Journal
Lung Cancer 34 Suppl 2:S35-41 (2001)
Reference
  Authors
Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF.
  Title
Apoptosis and lung cancer: a review.
  Journal
J Cell Biochem 88:885-98 (2003)
Reference
  Authors
Sartorius UA, Krammer PH.
  Title
Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
  Journal
Int J Cancer 97:584-92 (2002)
Reference
  Authors
Adhikary S, Eilers M.
  Title
Transcriptional regulation and transformation by Myc proteins.
  Journal
Nat Rev Mol Cell Biol 6:635-45 (2005)
Reference
  Authors
Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI.
  Title
A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.
  Journal
Mol Cell 7:639-50 (2001)
Reference
  Authors
Buttery RC, Rintoul RC, Sethi T.
  Title
Small cell lung cancer: the importance of the extracellular matrix.
  Journal
Int J Biochem Cell Biol 36:1154-60 (2004)
Reference
  Authors
Yamada KM, Araki M.
  Title
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.
  Journal
J Cell Sci 114:2375-82 (2001)
Reference
  Authors
Rintoul RC, Sethi T.
  Title
The role of extracellular matrix in small-cell lung cancer.
  Journal
Lancet Oncol 2:437-42 (2001)
Reference
  Authors
Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B.
  Title
Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells.
  Journal
Exp Cell Res 279:277-90 (2002)
Reference
  Authors
Osada H, Takahashi T.
  Title
Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.
  Journal
Oncogene 21:7421-34 (2002)
Reference
  Authors
Yokota J, Nishioka M, Tani M, Kohno T.
  Title
Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
  Journal
Clin Exp Metastasis 20:189-93 (2003)
Reference
  Authors
Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.
  Title
K-ras mutations in non-small-cell lung carcinoma: a review.
  Journal
Clin Lung Cancer 8:30-8 (2006)
Reference
  Authors
Pfeifer GP, Dammann R.
  Title
Methylation of the tumor suppressor gene RASSF1A in human tumors.
  Journal
Biochemistry (Mosc) 70:576-83 (2005)
Reference
  Authors
Altucci L, Gronemeyer H.
  Title
The promise of retinoids to fight against cancer.
  Journal
Nat Rev Cancer 1:181-93 (2001)
Reference
  Authors
Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF.
  Title
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.
  Journal
J Natl Cancer Inst 92:1303-7 (2000)
Reference
  Authors
Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA.
  Title
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
  Journal
Lung Cancer 41 Suppl 1:S29-42 (2003)
Reference
  Authors
Panani AD, Roussos C.
  Title
Cytogenetic and molecular aspects of lung cancer.
  Journal
Cancer Lett 239:1-9 (2006)
Reference
  Authors
Mitsuuchi Y, Testa JR.
  Title
Cytogenetics and molecular genetics of lung cancer.
  Journal
Am J Med Genet 115:183-8 (2002)
Reference
  Authors
Breuer RH, Postmus PE, Smit EF.
  Title
Molecular pathology of non-small-cell lung cancer.
  Journal
Respiration 72:313-30 (2005)
Reference
  Authors
Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.
  Title
Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.
  Journal
Clin Cancer Res 8:734-44 (2002)
Reference
  Authors
Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K.
  Title
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
  Journal
J Clin Pathol 58:1076-80 (2005)
Reference
  Authors
Lappano R, Maggiolini M
  Title
G protein-coupled receptors: novel targets for drug discovery in cancer.
  Journal
Nat Rev Drug Discov 10:47-60 (2011)
Reference
  Authors
O'Hayre M, Degese MS, Gutkind JS
  Title
Novel insights into G protein and G protein-coupled receptor signaling in cancer.
  Journal
Curr Opin Cell Biol 27:126-35 (2014)
Reference
  Authors
Dorsam RT, Gutkind JS
  Title
G-protein-coupled receptors and cancer.
  Journal
Nat Rev Cancer 7:79-94 (2007)
KO pathway
 

DBGET integrated database retrieval system